Gastric Adenocarcinoma

P2/3, N=429, Active, not recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> May 2026

P1/2, N=30, Completed, National Cancer Center Hospital East

P=N/A, N=129, Terminated, The University of Texas Health Science Center at San Antonio | Trial completion date: Jan 2030 --> Jun 2025 | Recruiting --> Terminated | Trial primary completion date: Jan 2030 --> Jun 2025; PI leaving institution

P1/2, N=164, Not yet recruiting, BigHat Biosciences, Inc.

First-line conversion therapy with oxaliplatin, fluoropyrimidine, sintilimab (a programmed death-1 inhibitor), and later trastuzumab yielded only transient stabilization followed by clear progression: After six cycles, AFP rose to 1 546.07 μg/L and target lymph nodes enlarged to 46 mm×31 mm on CT. Given treatment failure and persistent HER2 positivity, a second-line, biology-informed regimen was initiated: Disitamab vedotin (an HER2-targeted antibody-drug conjugate delivering monomethyl auristatin E), lenvatinib (a multi-targeted tyrosine kinase inhibitor blocking vascular endothelial growth factor receptor and other pro-angiogenic pathways), tislelizumab (a programmed death-1 inhibitor), and short-course capecitabine (discontinued after 7 days due to grade 3 thrombocytopenia)...This case underscores that in HER2-positive, chemotherapy-refractory HAS, a rationally designed, multimodal regimen integrating an HER2-directed antibody-drug conjugate, antiangiogenic agent, and immune checkpoint blockade can overcome therapeutic resistance, achieve meaningful downstaging, and enable long-term disease control. Early molecular characterization and aggressive, persona-lized intervention are essential for improving outcomes in this rare malignancy.

FOLH1 may be involved in tumor progression by regulating amino acid metabolic pathways and the immune microenvironment. It is a promising pan-cancer prognostic marker and synergistic target for immunotherapy.

Future studies should seek to confirm GAPLINC's clinical relevance, look at its therapeutic potential, and create focused RNA-based inhibitory techniques. Such initiatives might open the path for better patient outcomes for a variety of cancer types and more efficient therapies.

P1/2, N=36, Suspended, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Recruiting --> Suspended

A clearly clinically important Q-TWiST gain was observed with pembrolizumab plus chemotherapy versus chemotherapy in all participants. www.ClinicalTrials.gov identifier is NCT03675737.

HS1BP3 expression was found to correlate with expression of the invadopodia scaffold protein TKS5 and we show that the localisation of TKS5 inside multivesicular endosomes is increased in cells expressing an HS1BP3 PRR3.1 mutant. Overall, our results highlight the importance of the direct interaction between HS1BP3 and cortactin in cancer development by regulating cell proliferation, secretion and invasion, which may provide an explanation for the negative correlation between HS1BP3 levels and the survival of gastric adenocarcinoma and triple negative breast cancer patients.

This case illustrates the utility of quantitative CT enhancement analysis for characterizing the hypervascular phenotype of AFP-producing HAS and proposes a conceptual diagnostic framework to differentiate HAS from HCC. Multidisciplinary collaboration and systematic serum AFP screening in patients with gastric lesions are essential for optimal management of this aggressive malignancy.

P1/2, N=30, Completed, National Cancer Center Hospital East | Active, not recruiting --> Completed